
Graybug Vision, Inc. (NASDAQ: GRAY) Stock Competitors & Peer Comparison
See GRAY's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for GRAY and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| GRAY | $5.50 | -10.80% | 121M | -0.27 | -$20.63 | N/A |
| VRTX | $510.08 | +0.88% | 127.7B | 26.45 | $19.03 | N/A |
| MRNA | $225.00 | +14.52% | 78.2B | -24.17 | -$8.15 | N/A |
| REGN | $746.54 | +0.60% | 76.2B | 16.21 | $45.63 | +0.50% |
| VRNA | $106.91 | +0.11% | 72.7B | -102.80 | -$1.04 | N/A |
| ARGX | $825.03 | -11.14% | 50.9B | 29.52 | $27.73 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| RVMD | $189.76 | -5.53% | 40B | -21.33 | -$8.82 | N/A |
| ONC | $354.47 | -2.62% | 37.4B | 61.63 | $5.68 | N/A |
| RVMDW | $9.77 | -9.20% | 37.1B | -1.07 | -$8.82 | N/A |
Stock Comparison
Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX)
GRAY vs VRTX Comparison October 2026
Graybug Vision, Inc. (NASDAQ: GRAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRAY stands at 121M. In comparison, VRTX has a market cap of 127.7B. Regarding current trading prices, GRAY is priced at $5.50 on the NASDAQ, while VRTX trades at $510.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRAY currently has a P/E ratio of -0.27, whereas VRTX's P/E ratio is 26.45. In terms of profitability, GRAY's ROE is +33.98%, compared to VRTX's ROE of +0.23%. Regarding short-term risk, GRAY is more volatile compared to VRTX. This indicates higher risk in terms of short-term price fluctuations for GRAY.Check VRTX's competition here
Moderna, Inc. (NASDAQ: MRNA)
GRAY vs MRNA Comparison October 2026
Graybug Vision, Inc. (NASDAQ: GRAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRAY stands at 121M. In comparison, MRNA has a market cap of 78.2B. Regarding current trading prices, GRAY is priced at $5.50 on the NASDAQ, while MRNA trades at $225.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRAY currently has a P/E ratio of -0.27, whereas MRNA's P/E ratio is -24.17. In terms of profitability, GRAY's ROE is +33.98%, compared to MRNA's ROE of -0.39%. Regarding short-term risk, GRAY is more volatile compared to MRNA. This indicates higher risk in terms of short-term price fluctuations for GRAY.Check MRNA's competition here
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN)
GRAY vs REGN Comparison October 2026
Graybug Vision, Inc. (NASDAQ: GRAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRAY stands at 121M. In comparison, REGN has a market cap of 76.2B. Regarding current trading prices, GRAY is priced at $5.50 on the NASDAQ, while REGN trades at $746.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRAY currently has a P/E ratio of -0.27, whereas REGN's P/E ratio is 16.21. In terms of profitability, GRAY's ROE is +33.98%, compared to REGN's ROE of +0.14%. Regarding short-term risk, GRAY is more volatile compared to REGN. This indicates higher risk in terms of short-term price fluctuations for GRAY.Check REGN's competition here
Verona Pharma plc (NASDAQ: VRNA)
GRAY vs VRNA Comparison October 2026
Graybug Vision, Inc. (NASDAQ: GRAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRAY stands at 121M. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, GRAY is priced at $5.50 on the NASDAQ, while VRNA trades at $106.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRAY currently has a P/E ratio of -0.27, whereas VRNA's P/E ratio is -102.80. In terms of profitability, GRAY's ROE is +33.98%, compared to VRNA's ROE of -0.61%. Regarding short-term risk, GRAY is more volatile compared to VRNA. This indicates higher risk in terms of short-term price fluctuations for GRAY.Check VRNA's competition here
argenx SE (NASDAQ: ARGX)
GRAY vs ARGX Comparison October 2026
Graybug Vision, Inc. (NASDAQ: GRAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRAY stands at 121M. In comparison, ARGX has a market cap of 50.9B. Regarding current trading prices, GRAY is priced at $5.50 on the NASDAQ, while ARGX trades at $825.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRAY currently has a P/E ratio of -0.27, whereas ARGX's P/E ratio is 29.52. In terms of profitability, GRAY's ROE is +33.98%, compared to ARGX's ROE of +0.24%. Regarding short-term risk, GRAY is more volatile compared to ARGX. This indicates higher risk in terms of short-term price fluctuations for GRAY.Check ARGX's competition here
Seagen Inc. (NASDAQ: SGEN)
GRAY vs SGEN Comparison October 2026
Graybug Vision, Inc. (NASDAQ: GRAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRAY stands at 121M. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, GRAY is priced at $5.50 on the NASDAQ, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRAY currently has a P/E ratio of -0.27, whereas SGEN's P/E ratio is -57.19. In terms of profitability, GRAY's ROE is +33.98%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, GRAY is more volatile compared to SGEN. This indicates higher risk in terms of short-term price fluctuations for GRAY.Check SGEN's competition here
Revolution Medicines, Inc. (NASDAQ: RVMD)
GRAY vs RVMD Comparison October 2026
Graybug Vision, Inc. (NASDAQ: GRAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRAY stands at 121M. In comparison, RVMD has a market cap of 40B. Regarding current trading prices, GRAY is priced at $5.50 on the NASDAQ, while RVMD trades at $189.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRAY currently has a P/E ratio of -0.27, whereas RVMD's P/E ratio is -21.33. In terms of profitability, GRAY's ROE is +33.98%, compared to RVMD's ROE of -0.96%. Regarding short-term risk, GRAY is more volatile compared to RVMD. This indicates higher risk in terms of short-term price fluctuations for GRAY.Check RVMD's competition here
BeOne Medicines AG (NASDAQ: ONC)
GRAY vs ONC Comparison October 2026
Graybug Vision, Inc. (NASDAQ: GRAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRAY stands at 121M. In comparison, ONC has a market cap of 37.4B. Regarding current trading prices, GRAY is priced at $5.50 on the NASDAQ, while ONC trades at $354.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRAY currently has a P/E ratio of -0.27, whereas ONC's P/E ratio is 61.63. In terms of profitability, GRAY's ROE is +33.98%, compared to ONC's ROE of +0.14%. Regarding short-term risk, GRAY is more volatile compared to ONC. This indicates higher risk in terms of short-term price fluctuations for GRAY.Check ONC's competition here
Revolution Medicines, Inc. Warrant (NASDAQ: RVMDW)
GRAY vs RVMDW Comparison October 2026
Graybug Vision, Inc. (NASDAQ: GRAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRAY stands at 121M. In comparison, RVMDW has a market cap of 37.1B. Regarding current trading prices, GRAY is priced at $5.50 on the NASDAQ, while RVMDW trades at $9.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRAY currently has a P/E ratio of -0.27, whereas RVMDW's P/E ratio is -1.07. In terms of profitability, GRAY's ROE is +33.98%, compared to RVMDW's ROE of -0.96%. Regarding short-term risk, GRAY is more volatile compared to RVMDW. This indicates higher risk in terms of short-term price fluctuations for GRAY.Check RVMDW's competition here
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY)
GRAY vs ALNY Comparison October 2026
Graybug Vision, Inc. (NASDAQ: GRAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRAY stands at 121M. In comparison, ALNY has a market cap of 30B. Regarding current trading prices, GRAY is priced at $5.50 on the NASDAQ, while ALNY trades at $232.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRAY currently has a P/E ratio of -0.27, whereas ALNY's P/E ratio is 40.46. In terms of profitability, GRAY's ROE is +33.98%, compared to ALNY's ROE of +0.94%. Regarding short-term risk, GRAY is more volatile compared to ALNY. This indicates higher risk in terms of short-term price fluctuations for GRAY.Check ALNY's competition here
Roivant Sciences Ltd. (NASDAQ: ROIV)
GRAY vs ROIV Comparison October 2026
Graybug Vision, Inc. (NASDAQ: GRAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRAY stands at 121M. In comparison, ROIV has a market cap of 24.7B. Regarding current trading prices, GRAY is priced at $5.50 on the NASDAQ, while ROIV trades at $35.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRAY currently has a P/E ratio of -0.27, whereas ROIV's P/E ratio is -32.55. In terms of profitability, GRAY's ROE is +33.98%, compared to ROIV's ROE of -0.06%. Regarding short-term risk, GRAY is more volatile compared to ROIV. This indicates higher risk in terms of short-term price fluctuations for GRAY.Check ROIV's competition here
BioNTech SE (NASDAQ: BNTX)
GRAY vs BNTX Comparison October 2026
Graybug Vision, Inc. (NASDAQ: GRAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRAY stands at 121M. In comparison, BNTX has a market cap of 23.1B. Regarding current trading prices, GRAY is priced at $5.50 on the NASDAQ, while BNTX trades at $96.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRAY currently has a P/E ratio of -0.27, whereas BNTX's P/E ratio is -11.94. In terms of profitability, GRAY's ROE is +33.98%, compared to BNTX's ROE of -0.09%. Regarding short-term risk, GRAY is more volatile compared to BNTX. This indicates higher risk in terms of short-term price fluctuations for GRAY.Check BNTX's competition here
Incyte Corporation (NASDAQ: INCY)
GRAY vs INCY Comparison October 2026
Graybug Vision, Inc. (NASDAQ: GRAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRAY stands at 121M. In comparison, INCY has a market cap of 22.9B. Regarding current trading prices, GRAY is priced at $5.50 on the NASDAQ, while INCY trades at $112.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRAY currently has a P/E ratio of -0.27, whereas INCY's P/E ratio is 15.15. In terms of profitability, GRAY's ROE is +33.98%, compared to INCY's ROE of +0.30%. Regarding short-term risk, GRAY is more volatile compared to INCY. This indicates higher risk in terms of short-term price fluctuations for GRAY.Check INCY's competition here
United Therapeutics Corporation (NASDAQ: UTHR)
GRAY vs UTHR Comparison October 2026
Graybug Vision, Inc. (NASDAQ: GRAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRAY stands at 121M. In comparison, UTHR has a market cap of 22.6B. Regarding current trading prices, GRAY is priced at $5.50 on the NASDAQ, while UTHR trades at $549.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRAY currently has a P/E ratio of -0.27, whereas UTHR's P/E ratio is 19.06. In terms of profitability, GRAY's ROE is +33.98%, compared to UTHR's ROE of +0.20%. Regarding short-term risk, GRAY is more volatile compared to UTHR. This indicates higher risk in terms of short-term price fluctuations for GRAY.Check UTHR's competition here
Genmab A/S (NASDAQ: GMAB)
GRAY vs GMAB Comparison October 2026
Graybug Vision, Inc. (NASDAQ: GRAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRAY stands at 121M. In comparison, GMAB has a market cap of 22.1B. Regarding current trading prices, GRAY is priced at $5.50 on the NASDAQ, while GMAB trades at $37.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRAY currently has a P/E ratio of -0.27, whereas GMAB's P/E ratio is 27.17. In terms of profitability, GRAY's ROE is +33.98%, compared to GMAB's ROE of +0.14%. Regarding short-term risk, GRAY is more volatile compared to GMAB. This indicates higher risk in terms of short-term price fluctuations for GRAY.Check GMAB's competition here
Insmed Incorporated (NASDAQ: INSM)
GRAY vs INSM Comparison October 2026
Graybug Vision, Inc. (NASDAQ: GRAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRAY stands at 121M. In comparison, INSM has a market cap of 21.8B. Regarding current trading prices, GRAY is priced at $5.50 on the NASDAQ, while INSM trades at $100.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRAY currently has a P/E ratio of -0.27, whereas INSM's P/E ratio is -24.45. In terms of profitability, GRAY's ROE is +33.98%, compared to INSM's ROE of -1.11%. Regarding short-term risk, GRAY is more volatile compared to INSM. This indicates higher risk in terms of short-term price fluctuations for GRAY.Check INSM's competition here
BeiGene, Ltd. (NASDAQ: BGNE)
GRAY vs BGNE Comparison October 2026
Graybug Vision, Inc. (NASDAQ: GRAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRAY stands at 121M. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, GRAY is priced at $5.50 on the NASDAQ, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRAY currently has a P/E ratio of -0.27, whereas BGNE's P/E ratio is -22.55. In terms of profitability, GRAY's ROE is +33.98%, compared to BGNE's ROE of +0.14%. Regarding short-term risk, GRAY is more volatile compared to BGNE. This indicates higher risk in terms of short-term price fluctuations for GRAY.Check BGNE's competition here
Ginkgo Bioworks Holdings, Inc. WT (NYSE: DNA-WT)
GRAY vs DNA-WT Comparison October 2026
Graybug Vision, Inc. (NASDAQ: GRAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRAY stands at 121M. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, GRAY is priced at $5.50 on the NASDAQ, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRAY currently has a P/E ratio of -0.27, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, GRAY's ROE is +33.98%, compared to DNA-WT's ROE of -0.60%. Regarding short-term risk, GRAY is more volatile compared to DNA-WT. This indicates higher risk in terms of short-term price fluctuations for GRAY.Check DNA-WT's competition here
Exelixis, Inc. (NASDAQ: EXEL)
GRAY vs EXEL Comparison October 2026
Graybug Vision, Inc. (NASDAQ: GRAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRAY stands at 121M. In comparison, EXEL has a market cap of 14.8B. Regarding current trading prices, GRAY is priced at $5.50 on the NASDAQ, while EXEL trades at $59.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRAY currently has a P/E ratio of -0.27, whereas EXEL's P/E ratio is 16.86. In terms of profitability, GRAY's ROE is +33.98%, compared to EXEL's ROE of +0.42%. Regarding short-term risk, GRAY is more volatile compared to EXEL. This indicates higher risk in terms of short-term price fluctuations for GRAY.Check EXEL's competition here
Neurocrine Biosciences, Inc. (NASDAQ: NBIX)
GRAY vs NBIX Comparison October 2026
Graybug Vision, Inc. (NASDAQ: GRAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRAY stands at 121M. In comparison, NBIX has a market cap of 14.2B. Regarding current trading prices, GRAY is priced at $5.50 on the NASDAQ, while NBIX trades at $142.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRAY currently has a P/E ratio of -0.27, whereas NBIX's P/E ratio is 20.41. In terms of profitability, GRAY's ROE is +33.98%, compared to NBIX's ROE of +0.21%. Regarding short-term risk, GRAY is more volatile compared to NBIX. This indicates higher risk in terms of short-term price fluctuations for GRAY.Check NBIX's competition here
Jazz Pharmaceuticals plc (NASDAQ: JAZZ)
GRAY vs JAZZ Comparison October 2026
Graybug Vision, Inc. (NASDAQ: GRAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRAY stands at 121M. In comparison, JAZZ has a market cap of 14B. Regarding current trading prices, GRAY is priced at $5.50 on the NASDAQ, while JAZZ trades at $218.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRAY currently has a P/E ratio of -0.27, whereas JAZZ's P/E ratio is 8.29. In terms of profitability, GRAY's ROE is +33.98%, compared to JAZZ's ROE of +0.21%. Regarding short-term risk, GRAY is more volatile compared to JAZZ. This indicates higher risk in terms of short-term price fluctuations for GRAY.Check JAZZ's competition here
Ascendis Pharma A/S (NASDAQ: ASND)
GRAY vs ASND Comparison October 2026
Graybug Vision, Inc. (NASDAQ: GRAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRAY stands at 121M. In comparison, ASND has a market cap of 13.8B. Regarding current trading prices, GRAY is priced at $5.50 on the NASDAQ, while ASND trades at $229.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRAY currently has a P/E ratio of -0.27, whereas ASND's P/E ratio is -92.02. In terms of profitability, GRAY's ROE is +33.98%, compared to ASND's ROE of +1.90%. Regarding short-term risk, GRAY is more volatile compared to ASND. This indicates higher risk in terms of short-term price fluctuations for GRAY.Check ASND's competition here
Summit Therapeutics Inc. (NASDAQ: SMMT)
GRAY vs SMMT Comparison October 2026
Graybug Vision, Inc. (NASDAQ: GRAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRAY stands at 121M. In comparison, SMMT has a market cap of 13.7B. Regarding current trading prices, GRAY is priced at $5.50 on the NASDAQ, while SMMT trades at $17.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRAY currently has a P/E ratio of -0.27, whereas SMMT's P/E ratio is -15.33. In terms of profitability, GRAY's ROE is +33.98%, compared to SMMT's ROE of -2.04%. Regarding short-term risk, GRAY is more volatile compared to SMMT. This indicates higher risk in terms of short-term price fluctuations for GRAY.Check SMMT's competition here
Halozyme Therapeutics, Inc. (NASDAQ: HALO)
GRAY vs HALO Comparison October 2026
Graybug Vision, Inc. (NASDAQ: GRAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRAY stands at 121M. In comparison, HALO has a market cap of 13B. Regarding current trading prices, GRAY is priced at $5.50 on the NASDAQ, while HALO trades at $110.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRAY currently has a P/E ratio of -0.27, whereas HALO's P/E ratio is 20.49. In terms of profitability, GRAY's ROE is +33.98%, compared to HALO's ROE of +1.81%. Regarding short-term risk, GRAY is more volatile compared to HALO. This indicates higher risk in terms of short-term price fluctuations for GRAY.Check HALO's competition here
BridgeBio Pharma, Inc. (NASDAQ: BBIO)
GRAY vs BBIO Comparison October 2026
Graybug Vision, Inc. (NASDAQ: GRAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRAY stands at 121M. In comparison, BBIO has a market cap of 12.7B. Regarding current trading prices, GRAY is priced at $5.50 on the NASDAQ, while BBIO trades at $65.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRAY currently has a P/E ratio of -0.27, whereas BBIO's P/E ratio is -17.39. In terms of profitability, GRAY's ROE is +33.98%, compared to BBIO's ROE of +0.32%. Regarding short-term risk, GRAY is more volatile compared to BBIO. This indicates higher risk in terms of short-term price fluctuations for GRAY.Check BBIO's competition here
Karuna Therapeutics, Inc. (NASDAQ: KRTX)
GRAY vs KRTX Comparison October 2026
Graybug Vision, Inc. (NASDAQ: GRAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRAY stands at 121M. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, GRAY is priced at $5.50 on the NASDAQ, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRAY currently has a P/E ratio of -0.27, whereas KRTX's P/E ratio is -28.09. In terms of profitability, GRAY's ROE is +33.98%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, GRAY is more volatile compared to KRTX. This indicates higher risk in terms of short-term price fluctuations for GRAY.Check KRTX's competition here
Bio-Techne Corporation (NASDAQ: TECH)
GRAY vs TECH Comparison October 2026
Graybug Vision, Inc. (NASDAQ: GRAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRAY stands at 121M. In comparison, TECH has a market cap of 11.3B. Regarding current trading prices, GRAY is priced at $5.50 on the NASDAQ, while TECH trades at $72.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRAY currently has a P/E ratio of -0.27, whereas TECH's P/E ratio is 37.35. In terms of profitability, GRAY's ROE is +33.98%, compared to TECH's ROE of +0.09%. Regarding short-term risk, GRAY is more volatile compared to TECH. This indicates higher risk in terms of short-term price fluctuations for GRAY.Check TECH's competition here
Avidity Biosciences Inc (NASDAQ: RNAM)
GRAY vs RNAM Comparison October 2026
Graybug Vision, Inc. (NASDAQ: GRAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRAY stands at 121M. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, GRAY is priced at $5.50 on the NASDAQ, while RNAM trades at $72.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRAY currently has a P/E ratio of -0.27, whereas RNAM's P/E ratio is -17.39. In terms of profitability, GRAY's ROE is +33.98%, compared to RNAM's ROE of -0.36%. Regarding short-term risk, GRAY is more volatile compared to RNAM. This indicates higher risk in terms of short-term price fluctuations for GRAY.Check RNAM's competition here
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL)
GRAY vs MDGL Comparison October 2026
Graybug Vision, Inc. (NASDAQ: GRAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRAY stands at 121M. In comparison, MDGL has a market cap of 11B. Regarding current trading prices, GRAY is priced at $5.50 on the NASDAQ, while MDGL trades at $471.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRAY currently has a P/E ratio of -0.27, whereas MDGL's P/E ratio is -37.26. In terms of profitability, GRAY's ROE is +33.98%, compared to MDGL's ROE of -0.57%. Regarding short-term risk, GRAY is more volatile compared to MDGL. This indicates higher risk in terms of short-term price fluctuations for GRAY.Check MDGL's competition here
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN)
GRAY vs BMRN Comparison October 2026
Graybug Vision, Inc. (NASDAQ: GRAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRAY stands at 121M. In comparison, BMRN has a market cap of 10.6B. Regarding current trading prices, GRAY is priced at $5.50 on the NASDAQ, while BMRN trades at $54.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRAY currently has a P/E ratio of -0.27, whereas BMRN's P/E ratio is 26.39. In terms of profitability, GRAY's ROE is +33.98%, compared to BMRN's ROE of +0.01%. Regarding short-term risk, GRAY is more volatile compared to BMRN. This indicates higher risk in terms of short-term price fluctuations for GRAY.Check BMRN's competition here
ImmunityBio, Inc. (NASDAQ: IBRX)
GRAY vs IBRX Comparison October 2026
Graybug Vision, Inc. (NASDAQ: GRAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRAY stands at 121M. In comparison, IBRX has a market cap of 10.4B. Regarding current trading prices, GRAY is priced at $5.50 on the NASDAQ, while IBRX trades at $10.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRAY currently has a P/E ratio of -0.27, whereas IBRX's P/E ratio is -10.22. In terms of profitability, GRAY's ROE is +33.98%, compared to IBRX's ROE of +1.35%. Regarding short-term risk, GRAY is more volatile compared to IBRX. This indicates higher risk in terms of short-term price fluctuations for GRAY.Check IBRX's competition here
10x Genomics, Inc. (NASDAQ: TXG)
GRAY vs TXG Comparison October 2026
Graybug Vision, Inc. (NASDAQ: GRAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRAY stands at 121M. In comparison, TXG has a market cap of 9.8B. Regarding current trading prices, GRAY is priced at $5.50 on the NASDAQ, while TXG trades at $80.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRAY currently has a P/E ratio of -0.27, whereas TXG's P/E ratio is -130.98. In terms of profitability, GRAY's ROE is +33.98%, compared to TXG's ROE of -0.09%. Regarding short-term risk, GRAY is more volatile compared to TXG. This indicates higher risk in terms of short-term price fluctuations for GRAY.Check TXG's competition here
Krystal Biotech, Inc. (NASDAQ: KRYS)
GRAY vs KRYS Comparison October 2026
Graybug Vision, Inc. (NASDAQ: GRAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRAY stands at 121M. In comparison, KRYS has a market cap of 9.6B. Regarding current trading prices, GRAY is priced at $5.50 on the NASDAQ, while KRYS trades at $331.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRAY currently has a P/E ratio of -0.27, whereas KRYS's P/E ratio is 41.02. In terms of profitability, GRAY's ROE is +33.98%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, GRAY is more volatile compared to KRYS. This indicates higher risk in terms of short-term price fluctuations for GRAY.Check KRYS's competition here
Prometheus Biosciences, Inc. (NASDAQ: RXDX)
GRAY vs RXDX Comparison October 2026
Graybug Vision, Inc. (NASDAQ: GRAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRAY stands at 121M. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, GRAY is priced at $5.50 on the NASDAQ, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRAY currently has a P/E ratio of -0.27, whereas RXDX's P/E ratio is -56.47. In terms of profitability, GRAY's ROE is +33.98%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, GRAY is more volatile compared to RXDX. This indicates higher risk in terms of short-term price fluctuations for GRAY.Check RXDX's competition here
Twist Bioscience Corporation (NASDAQ: TWST)
GRAY vs TWST Comparison October 2026
Graybug Vision, Inc. (NASDAQ: GRAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRAY stands at 121M. In comparison, TWST has a market cap of 9.5B. Regarding current trading prices, GRAY is priced at $5.50 on the NASDAQ, while TWST trades at $159.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRAY currently has a P/E ratio of -0.27, whereas TWST's P/E ratio is -68.49. In terms of profitability, GRAY's ROE is +33.98%, compared to TWST's ROE of -0.30%. Regarding short-term risk, GRAY is more volatile compared to TWST. This indicates higher risk in terms of short-term price fluctuations for GRAY.Check TWST's competition here
Vaxcyte, Inc. (NASDAQ: PCVX)
GRAY vs PCVX Comparison October 2026
Graybug Vision, Inc. (NASDAQ: GRAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRAY stands at 121M. In comparison, PCVX has a market cap of 9.4B. Regarding current trading prices, GRAY is priced at $5.50 on the NASDAQ, while PCVX trades at $71.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRAY currently has a P/E ratio of -0.27, whereas PCVX's P/E ratio is -8.52. In terms of profitability, GRAY's ROE is +33.98%, compared to PCVX's ROE of -0.38%. Regarding short-term risk, GRAY is more volatile compared to PCVX. This indicates higher risk in terms of short-term price fluctuations for GRAY.Check PCVX's competition here
Nuvalent, Inc. (NASDAQ: NUVL)
GRAY vs NUVL Comparison October 2026
Graybug Vision, Inc. (NASDAQ: GRAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRAY stands at 121M. In comparison, NUVL has a market cap of 9.1B. Regarding current trading prices, GRAY is priced at $5.50 on the NASDAQ, while NUVL trades at $123.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRAY currently has a P/E ratio of -0.27, whereas NUVL's P/E ratio is -21.79. In terms of profitability, GRAY's ROE is +33.98%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, GRAY is more volatile compared to NUVL. This indicates higher risk in terms of short-term price fluctuations for GRAY.Check NUVL's competition here
Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX)
GRAY vs CRNX Comparison October 2026
Graybug Vision, Inc. (NASDAQ: GRAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRAY stands at 121M. In comparison, CRNX has a market cap of 9B. Regarding current trading prices, GRAY is priced at $5.50 on the NASDAQ, while CRNX trades at $84.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRAY currently has a P/E ratio of -0.27, whereas CRNX's P/E ratio is -16.86. In terms of profitability, GRAY's ROE is +33.98%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, GRAY is more volatile compared to CRNX. This indicates higher risk in terms of short-term price fluctuations for GRAY.Check CRNX's competition here
Protagonist Therapeutics, Inc. (NASDAQ: PTGX)
GRAY vs PTGX Comparison October 2026
Graybug Vision, Inc. (NASDAQ: GRAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRAY stands at 121M. In comparison, PTGX has a market cap of 9B. Regarding current trading prices, GRAY is priced at $5.50 on the NASDAQ, while PTGX trades at $143.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRAY currently has a P/E ratio of -0.27, whereas PTGX's P/E ratio is 135.83. In terms of profitability, GRAY's ROE is +33.98%, compared to PTGX's ROE of +0.12%. Regarding short-term risk, GRAY is more volatile compared to PTGX. This indicates higher risk in terms of short-term price fluctuations for GRAY.Check PTGX's competition here
Kymera Therapeutics, Inc. (NASDAQ: KYMR)
GRAY vs KYMR Comparison October 2026
Graybug Vision, Inc. (NASDAQ: GRAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRAY stands at 121M. In comparison, KYMR has a market cap of 9B. Regarding current trading prices, GRAY is priced at $5.50 on the NASDAQ, while KYMR trades at $112.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRAY currently has a P/E ratio of -0.27, whereas KYMR's P/E ratio is -34.16. In terms of profitability, GRAY's ROE is +33.98%, compared to KYMR's ROE of -0.22%. Regarding short-term risk, GRAY is more volatile compared to KYMR. This indicates higher risk in terms of short-term price fluctuations for GRAY.Check KYMR's competition here
Axsome Therapeutics, Inc. (NASDAQ: AXSM)
GRAY vs AXSM Comparison October 2026
Graybug Vision, Inc. (NASDAQ: GRAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRAY stands at 121M. In comparison, AXSM has a market cap of 8.8B. Regarding current trading prices, GRAY is priced at $5.50 on the NASDAQ, while AXSM trades at $168.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRAY currently has a P/E ratio of -0.27, whereas AXSM's P/E ratio is -44.41. In terms of profitability, GRAY's ROE is +33.98%, compared to AXSM's ROE of -2.56%. Regarding short-term risk, GRAY is more volatile compared to AXSM. This indicates higher risk in terms of short-term price fluctuations for GRAY.Check AXSM's competition here
ImmunoGen, Inc. (NASDAQ: IMGN)
GRAY vs IMGN Comparison October 2026
Graybug Vision, Inc. (NASDAQ: GRAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRAY stands at 121M. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, GRAY is priced at $5.50 on the NASDAQ, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRAY currently has a P/E ratio of -0.27, whereas IMGN's P/E ratio is -111.55. In terms of profitability, GRAY's ROE is +33.98%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, GRAY is more volatile compared to IMGN. This indicates higher risk in terms of short-term price fluctuations for GRAY.Check IMGN's competition here
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR)
GRAY vs ARWR Comparison October 2026
Graybug Vision, Inc. (NASDAQ: GRAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRAY stands at 121M. In comparison, ARWR has a market cap of 8.6B. Regarding current trading prices, GRAY is priced at $5.50 on the NASDAQ, while ARWR trades at $62.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRAY currently has a P/E ratio of -0.27, whereas ARWR's P/E ratio is -27.00. In terms of profitability, GRAY's ROE is +33.98%, compared to ARWR's ROE of -0.61%. Regarding short-term risk, GRAY is more volatile compared to ARWR. This indicates higher risk in terms of short-term price fluctuations for GRAY.Check ARWR's competition here
Apogee Therapeutics, Inc. (NASDAQ: APGE)
GRAY vs APGE Comparison October 2026
Graybug Vision, Inc. (NASDAQ: GRAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRAY stands at 121M. In comparison, APGE has a market cap of 8.4B. Regarding current trading prices, GRAY is priced at $5.50 on the NASDAQ, while APGE trades at $135.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRAY currently has a P/E ratio of -0.27, whereas APGE's P/E ratio is -31.19. In terms of profitability, GRAY's ROE is +33.98%, compared to APGE's ROE of -0.30%. Regarding short-term risk, GRAY is more volatile compared to APGE. This indicates higher risk in terms of short-term price fluctuations for GRAY.Check APGE's competition here
Blueprint Medicines Corporation (NASDAQ: BPMC)
GRAY vs BPMC Comparison October 2026
Graybug Vision, Inc. (NASDAQ: GRAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRAY stands at 121M. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, GRAY is priced at $5.50 on the NASDAQ, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRAY currently has a P/E ratio of -0.27, whereas BPMC's P/E ratio is -51.58. In terms of profitability, GRAY's ROE is +33.98%, compared to BPMC's ROE of -0.31%. Regarding short-term risk, GRAY is more volatile compared to BPMC. This indicates higher risk in terms of short-term price fluctuations for GRAY.Check BPMC's competition here
Cerevel Therapeutics Holdings, Inc. (NASDAQ: CERE)
GRAY vs CERE Comparison October 2026
Graybug Vision, Inc. (NASDAQ: GRAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRAY stands at 121M. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, GRAY is priced at $5.50 on the NASDAQ, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRAY currently has a P/E ratio of -0.27, whereas CERE's P/E ratio is -16.47. In terms of profitability, GRAY's ROE is +33.98%, compared to CERE's ROE of -0.72%. Regarding short-term risk, GRAY is more volatile compared to CERE. This indicates higher risk in terms of short-term price fluctuations for GRAY.Check CERE's competition here
TG Therapeutics, Inc. (NASDAQ: TGTX)
GRAY vs TGTX Comparison October 2026
Graybug Vision, Inc. (NASDAQ: GRAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRAY stands at 121M. In comparison, TGTX has a market cap of 8.2B. Regarding current trading prices, GRAY is priced at $5.50 on the NASDAQ, while TGTX trades at $55.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRAY currently has a P/E ratio of -0.27, whereas TGTX's P/E ratio is 19.33. In terms of profitability, GRAY's ROE is +33.98%, compared to TGTX's ROE of +0.72%. Regarding short-term risk, GRAY is more volatile compared to TGTX. This indicates higher risk in terms of short-term price fluctuations for GRAY.Check TGTX's competition here
Caris Life Sciences, Inc. (NASDAQ: CAI)
GRAY vs CAI Comparison October 2026
Graybug Vision, Inc. (NASDAQ: GRAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRAY stands at 121M. In comparison, CAI has a market cap of 7.8B. Regarding current trading prices, GRAY is priced at $5.50 on the NASDAQ, while CAI trades at $29.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRAY currently has a P/E ratio of -0.27, whereas CAI's P/E ratio is 77.27. In terms of profitability, GRAY's ROE is +33.98%, compared to CAI's ROE of +0.19%. Regarding short-term risk, GRAY is more volatile compared to CAI. This indicates higher risk in terms of short-term price fluctuations for GRAY.Check CAI's competition here
Cytokinetics, Incorporated (NASDAQ: CYTK)
GRAY vs CYTK Comparison October 2026
Graybug Vision, Inc. (NASDAQ: GRAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRAY stands at 121M. In comparison, CYTK has a market cap of 7.7B. Regarding current trading prices, GRAY is priced at $5.50 on the NASDAQ, while CYTK trades at $62.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRAY currently has a P/E ratio of -0.27, whereas CYTK's P/E ratio is -8.59. In terms of profitability, GRAY's ROE is +33.98%, compared to CYTK's ROE of +1.64%. Regarding short-term risk, GRAY is more volatile compared to CYTK. This indicates higher risk in terms of short-term price fluctuations for GRAY.Check CYTK's competition here
Metsera, Inc. (NASDAQ: MTSR)
GRAY vs MTSR Comparison October 2026
Graybug Vision, Inc. (NASDAQ: GRAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRAY stands at 121M. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, GRAY is priced at $5.50 on the NASDAQ, while MTSR trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRAY currently has a P/E ratio of -0.27, whereas MTSR's P/E ratio is -23.58. In terms of profitability, GRAY's ROE is +33.98%, compared to MTSR's ROE of -0.47%. Regarding short-term risk, GRAY is more volatile compared to MTSR. This indicates higher risk in terms of short-term price fluctuations for GRAY.Check MTSR's competition here
Praxis Precision Medicines, Inc. (NASDAQ: PRAX)
GRAY vs PRAX Comparison October 2026
Graybug Vision, Inc. (NASDAQ: GRAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRAY stands at 121M. In comparison, PRAX has a market cap of 7.3B. Regarding current trading prices, GRAY is priced at $5.50 on the NASDAQ, while PRAX trades at $259.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRAY currently has a P/E ratio of -0.27, whereas PRAX's P/E ratio is -20.38. In terms of profitability, GRAY's ROE is +33.98%, compared to PRAX's ROE of -0.34%. Regarding short-term risk, GRAY is more volatile compared to PRAX. This indicates higher risk in terms of short-term price fluctuations for GRAY.Check PRAX's competition here
Ionis Pharmaceuticals, Inc. (NASDAQ: IONS)
GRAY vs IONS Comparison October 2026
Graybug Vision, Inc. (NASDAQ: GRAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRAY stands at 121M. In comparison, IONS has a market cap of 7.2B. Regarding current trading prices, GRAY is priced at $5.50 on the NASDAQ, while IONS trades at $45.28.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRAY currently has a P/E ratio of -0.27, whereas IONS's P/E ratio is -13.24. In terms of profitability, GRAY's ROE is +33.98%, compared to IONS's ROE of -1.11%. Regarding short-term risk, GRAY is more volatile compared to IONS. This indicates higher risk in terms of short-term price fluctuations for GRAY.Check IONS's competition here
Spyre Therapeutics, Inc. (NASDAQ: SYRE)
GRAY vs SYRE Comparison October 2026
Graybug Vision, Inc. (NASDAQ: GRAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRAY stands at 121M. In comparison, SYRE has a market cap of 6.9B. Regarding current trading prices, GRAY is priced at $5.50 on the NASDAQ, while SYRE trades at $85.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRAY currently has a P/E ratio of -0.27, whereas SYRE's P/E ratio is -40.97. In terms of profitability, GRAY's ROE is +33.98%, compared to SYRE's ROE of -0.24%. Regarding short-term risk, GRAY is more volatile compared to SYRE. This indicates higher risk in terms of short-term price fluctuations for GRAY.Check SYRE's competition here
Merus N.V. (NASDAQ: MRUS)
GRAY vs MRUS Comparison October 2026
Graybug Vision, Inc. (NASDAQ: GRAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRAY stands at 121M. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, GRAY is priced at $5.50 on the NASDAQ, while MRUS trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRAY currently has a P/E ratio of -0.27, whereas MRUS's P/E ratio is -17.05. In terms of profitability, GRAY's ROE is +33.98%, compared to MRUS's ROE of -0.31%. Regarding short-term risk, GRAY is more volatile compared to MRUS. This indicates higher risk in terms of short-term price fluctuations for GRAY.Check MRUS's competition here
Arcellx, Inc. (NASDAQ: ACLX)
GRAY vs ACLX Comparison October 2026
Graybug Vision, Inc. (NASDAQ: GRAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRAY stands at 121M. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, GRAY is priced at $5.50 on the NASDAQ, while ACLX trades at $115.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRAY currently has a P/E ratio of -0.27, whereas ACLX's P/E ratio is -28.27. In terms of profitability, GRAY's ROE is +33.98%, compared to ACLX's ROE of -0.40%. Regarding short-term risk, GRAY is more volatile compared to ACLX. This indicates higher risk in terms of short-term price fluctuations for GRAY.Check ACLX's competition here
Reata Pharmaceuticals, Inc. (NASDAQ: RETA)
GRAY vs RETA Comparison October 2026
Graybug Vision, Inc. (NASDAQ: GRAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRAY stands at 121M. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, GRAY is priced at $5.50 on the NASDAQ, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRAY currently has a P/E ratio of -0.27, whereas RETA's P/E ratio is -66.29. In terms of profitability, GRAY's ROE is +33.98%, compared to RETA's ROE of +0.47%. Regarding short-term risk, GRAY is more volatile compared to RETA. This indicates higher risk in terms of short-term price fluctuations for GRAY.Check RETA's competition here
Abivax S.A. (NASDAQ: ABVX)
GRAY vs ABVX Comparison October 2026
Graybug Vision, Inc. (NASDAQ: GRAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRAY stands at 121M. In comparison, ABVX has a market cap of 6.5B. Regarding current trading prices, GRAY is priced at $5.50 on the NASDAQ, while ABVX trades at $88.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRAY currently has a P/E ratio of -0.27, whereas ABVX's P/E ratio is -14.59. In terms of profitability, GRAY's ROE is +33.98%, compared to ABVX's ROE of -0.99%. Regarding short-term risk, GRAY is more volatile compared to ABVX. This indicates higher risk in terms of short-term price fluctuations for GRAY.Check ABVX's competition here
Centessa Pharmaceuticals plc (NASDAQ: CNTA)
GRAY vs CNTA Comparison October 2026
Graybug Vision, Inc. (NASDAQ: GRAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRAY stands at 121M. In comparison, CNTA has a market cap of 6.3B. Regarding current trading prices, GRAY is priced at $5.50 on the NASDAQ, while CNTA trades at $40.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRAY currently has a P/E ratio of -0.27, whereas CNTA's P/E ratio is -22.63. In terms of profitability, GRAY's ROE is +33.98%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, GRAY is more volatile compared to CNTA. This indicates higher risk in terms of short-term price fluctuations for GRAY.Check CNTA's competition here
Immunovant, Inc. (NASDAQ: IMVT)
GRAY vs IMVT Comparison October 2026
Graybug Vision, Inc. (NASDAQ: GRAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRAY stands at 121M. In comparison, IMVT has a market cap of 6.2B. Regarding current trading prices, GRAY is priced at $5.50 on the NASDAQ, while IMVT trades at $30.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRAY currently has a P/E ratio of -0.27, whereas IMVT's P/E ratio is -10.73. In terms of profitability, GRAY's ROE is +33.98%, compared to IMVT's ROE of -0.70%. Regarding short-term risk, GRAY is more volatile compared to IMVT. This indicates higher risk in terms of short-term price fluctuations for GRAY.Check IMVT's competition here
Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM)
GRAY vs RYTM Comparison October 2026
Graybug Vision, Inc. (NASDAQ: GRAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRAY stands at 121M. In comparison, RYTM has a market cap of 6.1B. Regarding current trading prices, GRAY is priced at $5.50 on the NASDAQ, while RYTM trades at $90.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRAY currently has a P/E ratio of -0.27, whereas RYTM's P/E ratio is -28.82. In terms of profitability, GRAY's ROE is +33.98%, compared to RYTM's ROE of -0.80%. Regarding short-term risk, GRAY is more volatile compared to RYTM. This indicates higher risk in terms of short-term price fluctuations for GRAY.Check RYTM's competition here
Belite Bio, Inc (NASDAQ: BLTE)
GRAY vs BLTE Comparison October 2026
Graybug Vision, Inc. (NASDAQ: GRAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRAY stands at 121M. In comparison, BLTE has a market cap of 6.1B. Regarding current trading prices, GRAY is priced at $5.50 on the NASDAQ, while BLTE trades at $154.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRAY currently has a P/E ratio of -0.27, whereas BLTE's P/E ratio is -81.56. In terms of profitability, GRAY's ROE is +33.98%, compared to BLTE's ROE of -0.16%. Regarding short-term risk, GRAY is more volatile compared to BLTE. This indicates higher risk in terms of short-term price fluctuations for GRAY.Check BLTE's competition here
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA)
GRAY vs IOVA Comparison October 2026
Graybug Vision, Inc. (NASDAQ: GRAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRAY stands at 121M. In comparison, IOVA has a market cap of 5.9B. Regarding current trading prices, GRAY is priced at $5.50 on the NASDAQ, while IOVA trades at $14.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRAY currently has a P/E ratio of -0.27, whereas IOVA's P/E ratio is -18.23. In terms of profitability, GRAY's ROE is +33.98%, compared to IOVA's ROE of -0.41%. Regarding short-term risk, GRAY is more volatile compared to IOVA. This indicates higher risk in terms of short-term price fluctuations for GRAY.Check IOVA's competition here
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND)
GRAY vs LGND Comparison October 2026
Graybug Vision, Inc. (NASDAQ: GRAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRAY stands at 121M. In comparison, LGND has a market cap of 5.9B. Regarding current trading prices, GRAY is priced at $5.50 on the NASDAQ, while LGND trades at $301.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRAY currently has a P/E ratio of -0.27, whereas LGND's P/E ratio is 32.38. In terms of profitability, GRAY's ROE is +33.98%, compared to LGND's ROE of +0.20%. Regarding short-term risk, GRAY is more volatile compared to LGND. This indicates higher risk in terms of short-term price fluctuations for GRAY.Check LGND's competition here
Kodiak Sciences Inc. (NASDAQ: KOD)
GRAY vs KOD Comparison October 2026
Graybug Vision, Inc. (NASDAQ: GRAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRAY stands at 121M. In comparison, KOD has a market cap of 5.9B. Regarding current trading prices, GRAY is priced at $5.50 on the NASDAQ, while KOD trades at $99.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRAY currently has a P/E ratio of -0.27, whereas KOD's P/E ratio is -22.60. In terms of profitability, GRAY's ROE is +33.98%, compared to KOD's ROE of -2.73%. Regarding short-term risk, GRAY is more volatile compared to KOD. This indicates higher risk in terms of short-term price fluctuations for GRAY.Check KOD's competition here
Cidara Therapeutics, Inc. (NASDAQ: CDTX)
GRAY vs CDTX Comparison October 2026
Graybug Vision, Inc. (NASDAQ: GRAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRAY stands at 121M. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, GRAY is priced at $5.50 on the NASDAQ, while CDTX trades at $221.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRAY currently has a P/E ratio of -0.27, whereas CDTX's P/E ratio is -19.77. In terms of profitability, GRAY's ROE is +33.98%, compared to CDTX's ROE of -0.24%. Regarding short-term risk, GRAY is more volatile compared to CDTX. This indicates higher risk in terms of short-term price fluctuations for GRAY.Check CDTX's competition here
CG Oncology Inc. (NASDAQ: CGON)
GRAY vs CGON Comparison October 2026
Graybug Vision, Inc. (NASDAQ: GRAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRAY stands at 121M. In comparison, CGON has a market cap of 5.6B. Regarding current trading prices, GRAY is priced at $5.50 on the NASDAQ, while CGON trades at $63.82.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRAY currently has a P/E ratio of -0.27, whereas CGON's P/E ratio is -23.52. In terms of profitability, GRAY's ROE is +33.98%, compared to CGON's ROE of -0.25%. Regarding short-term risk, GRAY is more volatile compared to CGON. This indicates higher risk in terms of short-term price fluctuations for GRAY.Check CGON's competition here
Abcam plc (NASDAQ: ABCM)
GRAY vs ABCM Comparison October 2026
Graybug Vision, Inc. (NASDAQ: GRAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRAY stands at 121M. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, GRAY is priced at $5.50 on the NASDAQ, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRAY currently has a P/E ratio of -0.27, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, GRAY's ROE is +33.98%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, GRAY is more volatile compared to ABCM. This indicates higher risk in terms of short-term price fluctuations for GRAY.Check ABCM's competition here
IVERIC bio, Inc. (NASDAQ: ISEE)
GRAY vs ISEE Comparison October 2026
Graybug Vision, Inc. (NASDAQ: GRAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRAY stands at 121M. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, GRAY is priced at $5.50 on the NASDAQ, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRAY currently has a P/E ratio of -0.27, whereas ISEE's P/E ratio is -22.44. In terms of profitability, GRAY's ROE is +33.98%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, GRAY is more volatile compared to ISEE. This indicates higher risk in terms of short-term price fluctuations for GRAY.Check ISEE's competition here
Erasca, Inc. (NASDAQ: ERAS)
GRAY vs ERAS Comparison October 2026
Graybug Vision, Inc. (NASDAQ: GRAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRAY stands at 121M. In comparison, ERAS has a market cap of 5.4B. Regarding current trading prices, GRAY is priced at $5.50 on the NASDAQ, while ERAS trades at $16.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRAY currently has a P/E ratio of -0.27, whereas ERAS's P/E ratio is -16.62. In terms of profitability, GRAY's ROE is +33.98%, compared to ERAS's ROE of -0.80%. Regarding short-term risk, GRAY is more volatile compared to ERAS. This indicates higher risk in terms of short-term price fluctuations for GRAY.Check ERAS's competition here
Veradermics, Incorporated (NYSE: MANE)
GRAY vs MANE Comparison October 2026
Graybug Vision, Inc. (NASDAQ: GRAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRAY stands at 121M. In comparison, MANE has a market cap of 5.3B. Regarding current trading prices, GRAY is priced at $5.50 on the NASDAQ, while MANE trades at $130.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRAY currently has a P/E ratio of -0.27, whereas MANE's P/E ratio is -40.34. In terms of profitability, GRAY's ROE is +33.98%, compared to MANE's ROE of -0.38%. Regarding short-term risk, GRAY is more volatile compared to MANE. This indicates higher risk in terms of short-term price fluctuations for GRAY.Check MANE's competition here
Apellis Pharmaceuticals, Inc. (NASDAQ: APLS)
GRAY vs APLS Comparison October 2026
Graybug Vision, Inc. (NASDAQ: GRAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRAY stands at 121M. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, GRAY is priced at $5.50 on the NASDAQ, while APLS trades at $41.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRAY currently has a P/E ratio of -0.27, whereas APLS's P/E ratio is 38.35. In terms of profitability, GRAY's ROE is +33.98%, compared to APLS's ROE of +0.40%. Regarding short-term risk, GRAY is more volatile compared to APLS. This indicates higher risk in terms of short-term price fluctuations for GRAY.Check APLS's competition here
PTC Therapeutics, Inc. (NASDAQ: PTCT)
GRAY vs PTCT Comparison October 2026
Graybug Vision, Inc. (NASDAQ: GRAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRAY stands at 121M. In comparison, PTCT has a market cap of 5.2B. Regarding current trading prices, GRAY is priced at $5.50 on the NASDAQ, while PTCT trades at $64.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRAY currently has a P/E ratio of -0.27, whereas PTCT's P/E ratio is -26.85. In terms of profitability, GRAY's ROE is +33.98%, compared to PTCT's ROE of +0.22%. Regarding short-term risk, GRAY is more volatile compared to PTCT. This indicates higher risk in terms of short-term price fluctuations for GRAY.Check PTCT's competition here
Cogent Biosciences, Inc. (NASDAQ: COGT)
GRAY vs COGT Comparison October 2026
Graybug Vision, Inc. (NASDAQ: GRAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRAY stands at 121M. In comparison, COGT has a market cap of 5.1B. Regarding current trading prices, GRAY is priced at $5.50 on the NASDAQ, while COGT trades at $31.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRAY currently has a P/E ratio of -0.27, whereas COGT's P/E ratio is -14.26. In terms of profitability, GRAY's ROE is +33.98%, compared to COGT's ROE of -0.73%. Regarding short-term risk, GRAY is more volatile compared to COGT. This indicates higher risk in terms of short-term price fluctuations for GRAY.Check COGT's competition here
Scholar Rock Holding Corporation (NASDAQ: SRRK)
GRAY vs SRRK Comparison October 2026
Graybug Vision, Inc. (NASDAQ: GRAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRAY stands at 121M. In comparison, SRRK has a market cap of 5.1B. Regarding current trading prices, GRAY is priced at $5.50 on the NASDAQ, while SRRK trades at $42.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRAY currently has a P/E ratio of -0.27, whereas SRRK's P/E ratio is -12.23. In terms of profitability, GRAY's ROE is +33.98%, compared to SRRK's ROE of -1.60%. Regarding short-term risk, GRAY is more volatile compared to SRRK. This indicates higher risk in terms of short-term price fluctuations for GRAY.Check SRRK's competition here
Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM)
GRAY vs MIRM Comparison October 2026
Graybug Vision, Inc. (NASDAQ: GRAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRAY stands at 121M. In comparison, MIRM has a market cap of 5B. Regarding current trading prices, GRAY is priced at $5.50 on the NASDAQ, while MIRM trades at $86.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRAY currently has a P/E ratio of -0.27, whereas MIRM's P/E ratio is -5.59. In terms of profitability, GRAY's ROE is +33.98%, compared to MIRM's ROE of -4.10%. Regarding short-term risk, GRAY is more volatile compared to MIRM. This indicates higher risk in terms of short-term price fluctuations for GRAY.Check MIRM's competition here
CRISPR Therapeutics AG (NASDAQ: CRSP)
GRAY vs CRSP Comparison October 2026
Graybug Vision, Inc. (NASDAQ: GRAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRAY stands at 121M. In comparison, CRSP has a market cap of 4.9B. Regarding current trading prices, GRAY is priced at $5.50 on the NASDAQ, while CRSP trades at $53.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRAY currently has a P/E ratio of -0.27, whereas CRSP's P/E ratio is -10.60. In terms of profitability, GRAY's ROE is +33.98%, compared to CRSP's ROE of -0.24%. Regarding short-term risk, GRAY is more volatile compared to CRSP. This indicates higher risk in terms of short-term price fluctuations for GRAY.Check CRSP's competition here
Travere Therapeutics, Inc. (NASDAQ: TVTX)
GRAY vs TVTX Comparison October 2026
Graybug Vision, Inc. (NASDAQ: GRAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRAY stands at 121M. In comparison, TVTX has a market cap of 4.8B. Regarding current trading prices, GRAY is priced at $5.50 on the NASDAQ, while TVTX trades at $52.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRAY currently has a P/E ratio of -0.27, whereas TVTX's P/E ratio is -115.64. In terms of profitability, GRAY's ROE is +33.98%, compared to TVTX's ROE of -0.56%. Regarding short-term risk, GRAY is more volatile compared to TVTX. This indicates higher risk in terms of short-term price fluctuations for GRAY.Check TVTX's competition here
Terns Pharmaceuticals, Inc. (NASDAQ: TERN)
GRAY vs TERN Comparison October 2026
Graybug Vision, Inc. (NASDAQ: GRAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRAY stands at 121M. In comparison, TERN has a market cap of 4.8B. Regarding current trading prices, GRAY is priced at $5.50 on the NASDAQ, while TERN trades at $52.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRAY currently has a P/E ratio of -0.27, whereas TERN's P/E ratio is -51.41. In terms of profitability, GRAY's ROE is +33.98%, compared to TERN's ROE of -0.14%. Regarding short-term risk, GRAY is more volatile compared to TERN. This indicates higher risk in terms of short-term price fluctuations for GRAY.Check TERN's competition here
Oruka Therapeutics, Inc. (NASDAQ: ORKA)
GRAY vs ORKA Comparison October 2026
Graybug Vision, Inc. (NASDAQ: GRAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRAY stands at 121M. In comparison, ORKA has a market cap of 4.7B. Regarding current trading prices, GRAY is priced at $5.50 on the NASDAQ, while ORKA trades at $82.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRAY currently has a P/E ratio of -0.27, whereas ORKA's P/E ratio is -39.84. In terms of profitability, GRAY's ROE is +33.98%, compared to ORKA's ROE of -0.21%. Regarding short-term risk, GRAY is more volatile compared to ORKA. This indicates higher risk in terms of short-term price fluctuations for GRAY.Check ORKA's competition here
Dianthus Therapeutics, Inc. (NASDAQ: DNTH)
GRAY vs DNTH Comparison October 2026
Graybug Vision, Inc. (NASDAQ: GRAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRAY stands at 121M. In comparison, DNTH has a market cap of 4.6B. Regarding current trading prices, GRAY is priced at $5.50 on the NASDAQ, while DNTH trades at $82.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRAY currently has a P/E ratio of -0.27, whereas DNTH's P/E ratio is -19.86. In terms of profitability, GRAY's ROE is +33.98%, compared to DNTH's ROE of -0.04%. Regarding short-term risk, GRAY is more volatile compared to DNTH. This indicates higher risk in terms of short-term price fluctuations for GRAY.Check DNTH's competition here
Amicus Therapeutics, Inc. (NASDAQ: FOLD)
GRAY vs FOLD Comparison October 2026
Graybug Vision, Inc. (NASDAQ: GRAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRAY stands at 121M. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, GRAY is priced at $5.50 on the NASDAQ, while FOLD trades at $14.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRAY currently has a P/E ratio of -0.27, whereas FOLD's P/E ratio is -161.00. In terms of profitability, GRAY's ROE is +33.98%, compared to FOLD's ROE of -0.02%. Regarding short-term risk, GRAY is more volatile compared to FOLD. This indicates higher risk in terms of short-term price fluctuations for GRAY.Check FOLD's competition here
Definium Therapeutics, Inc. (NASDAQ: DFTX)
GRAY vs DFTX Comparison October 2026
Graybug Vision, Inc. (NASDAQ: GRAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRAY stands at 121M. In comparison, DFTX has a market cap of 4.5B. Regarding current trading prices, GRAY is priced at $5.50 on the NASDAQ, while DFTX trades at $36.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRAY currently has a P/E ratio of -0.27, whereas DFTX's P/E ratio is N/A. In terms of profitability, GRAY's ROE is +33.98%, compared to DFTX's ROE of -0.85%. Regarding short-term risk, GRAY is more volatile compared to DFTX. This indicates higher risk in terms of short-term price fluctuations for GRAY.Check DFTX's competition here
Akero Therapeutics, Inc. (NASDAQ: AKRO)
GRAY vs AKRO Comparison October 2026
Graybug Vision, Inc. (NASDAQ: GRAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRAY stands at 121M. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, GRAY is priced at $5.50 on the NASDAQ, while AKRO trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRAY currently has a P/E ratio of -0.27, whereas AKRO's P/E ratio is -14.57. In terms of profitability, GRAY's ROE is +33.98%, compared to AKRO's ROE of -0.15%. Regarding short-term risk, GRAY is more volatile compared to AKRO. This indicates higher risk in terms of short-term price fluctuations for GRAY.Check AKRO's competition here
Alpine Immune Sciences, Inc. (NASDAQ: ALPN)
GRAY vs ALPN Comparison October 2026
Graybug Vision, Inc. (NASDAQ: GRAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRAY stands at 121M. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, GRAY is priced at $5.50 on the NASDAQ, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRAY currently has a P/E ratio of -0.27, whereas ALPN's P/E ratio is -101.52. In terms of profitability, GRAY's ROE is +33.98%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, GRAY is more volatile compared to ALPN. This indicates higher risk in terms of short-term price fluctuations for GRAY.Check ALPN's competition here
Opthea Limited (NASDAQ: OPT)
GRAY vs OPT Comparison October 2026
Graybug Vision, Inc. (NASDAQ: GRAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRAY stands at 121M. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, GRAY is priced at $5.50 on the NASDAQ, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRAY currently has a P/E ratio of -0.27, whereas OPT's P/E ratio is -1.52. In terms of profitability, GRAY's ROE is +33.98%, compared to OPT's ROE of +1.18%. Regarding short-term risk, GRAY is more volatile compared to OPT. This indicates higher risk in terms of short-term price fluctuations for GRAY.Check OPT's competition here
PureTech Health plc (NASDAQ: PRTC)
GRAY vs PRTC Comparison October 2026
Graybug Vision, Inc. (NASDAQ: GRAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRAY stands at 121M. In comparison, PRTC has a market cap of 4.2B. Regarding current trading prices, GRAY is priced at $5.50 on the NASDAQ, while PRTC trades at $17.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRAY currently has a P/E ratio of -0.27, whereas PRTC's P/E ratio is -3.78. In terms of profitability, GRAY's ROE is +33.98%, compared to PRTC's ROE of -0.32%. Regarding short-term risk, GRAY is more volatile compared to PRTC. This indicates higher risk in terms of short-term price fluctuations for GRAY.Check PRTC's competition here
Edgewise Therapeutics, Inc. (NASDAQ: EWTX)
GRAY vs EWTX Comparison October 2026
Graybug Vision, Inc. (NASDAQ: GRAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRAY stands at 121M. In comparison, EWTX has a market cap of 4.2B. Regarding current trading prices, GRAY is priced at $5.50 on the NASDAQ, while EWTX trades at $39.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRAY currently has a P/E ratio of -0.27, whereas EWTX's P/E ratio is -21.21. In terms of profitability, GRAY's ROE is +33.98%, compared to EWTX's ROE of -0.39%. Regarding short-term risk, GRAY is more volatile compared to EWTX. This indicates higher risk in terms of short-term price fluctuations for GRAY.Check EWTX's competition here
Adaptive Biotechnologies Corporation (NASDAQ: ADPT)
GRAY vs ADPT Comparison October 2026
Graybug Vision, Inc. (NASDAQ: GRAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRAY stands at 121M. In comparison, ADPT has a market cap of 4.2B. Regarding current trading prices, GRAY is priced at $5.50 on the NASDAQ, while ADPT trades at $26.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRAY currently has a P/E ratio of -0.27, whereas ADPT's P/E ratio is -63.63. In terms of profitability, GRAY's ROE is +33.98%, compared to ADPT's ROE of -0.33%. Regarding short-term risk, GRAY is more volatile compared to ADPT. This indicates higher risk in terms of short-term price fluctuations for GRAY.Check ADPT's competition here
Mirati Therapeutics, Inc. (NASDAQ: MRTX)
GRAY vs MRTX Comparison October 2026
Graybug Vision, Inc. (NASDAQ: GRAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRAY stands at 121M. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, GRAY is priced at $5.50 on the NASDAQ, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRAY currently has a P/E ratio of -0.27, whereas MRTX's P/E ratio is -4.82. In terms of profitability, GRAY's ROE is +33.98%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, GRAY is more volatile compared to MRTX. This indicates higher risk in terms of short-term price fluctuations for GRAY.Check MRTX's competition here
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX)
GRAY vs CPRX Comparison October 2026
Graybug Vision, Inc. (NASDAQ: GRAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRAY stands at 121M. In comparison, CPRX has a market cap of 3.9B. Regarding current trading prices, GRAY is priced at $5.50 on the NASDAQ, while CPRX trades at $31.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRAY currently has a P/E ratio of -0.27, whereas CPRX's P/E ratio is 17.49. In terms of profitability, GRAY's ROE is +33.98%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, GRAY is more volatile compared to CPRX. This indicates higher risk in terms of short-term price fluctuations for GRAY.Check CPRX's competition here
Relay Therapeutics, Inc. (NASDAQ: RLAY)
GRAY vs RLAY Comparison October 2026
Graybug Vision, Inc. (NASDAQ: GRAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRAY stands at 121M. In comparison, RLAY has a market cap of 3.8B. Regarding current trading prices, GRAY is priced at $5.50 on the NASDAQ, while RLAY trades at $17.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRAY currently has a P/E ratio of -0.27, whereas RLAY's P/E ratio is -11.09. In terms of profitability, GRAY's ROE is +33.98%, compared to RLAY's ROE of -0.42%. Regarding short-term risk, GRAY is more volatile compared to RLAY. This indicates higher risk in terms of short-term price fluctuations for GRAY.Check RLAY's competition here
RayzeBio, Inc. Common Stock (NASDAQ: RYZB)
GRAY vs RYZB Comparison October 2026
Graybug Vision, Inc. (NASDAQ: GRAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRAY stands at 121M. In comparison, RYZB has a market cap of 3.8B. Regarding current trading prices, GRAY is priced at $5.50 on the NASDAQ, while RYZB trades at $62.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRAY currently has a P/E ratio of -0.27, whereas RYZB's P/E ratio is -57.86. In terms of profitability, GRAY's ROE is +33.98%, compared to RYZB's ROE of +0.83%. Regarding short-term risk, GRAY is more volatile compared to RYZB. This indicates higher risk in terms of short-term price fluctuations for GRAY.Check RYZB's competition here
Telix Pharmaceuticals Limited (NASDAQ: TLX)
GRAY vs TLX Comparison October 2026
Graybug Vision, Inc. (NASDAQ: GRAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRAY stands at 121M. In comparison, TLX has a market cap of 3.7B. Regarding current trading prices, GRAY is priced at $5.50 on the NASDAQ, while TLX trades at $11.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRAY currently has a P/E ratio of -0.27, whereas TLX's P/E ratio is 114.93. In terms of profitability, GRAY's ROE is +33.98%, compared to TLX's ROE of +0.07%. Regarding short-term risk, GRAY is more volatile compared to TLX. This indicates higher risk in terms of short-term price fluctuations for GRAY.Check TLX's competition here
CymaBay Therapeutics, Inc. (NASDAQ: CBAY)
GRAY vs CBAY Comparison October 2026
Graybug Vision, Inc. (NASDAQ: GRAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRAY stands at 121M. In comparison, CBAY has a market cap of 3.7B. Regarding current trading prices, GRAY is priced at $5.50 on the NASDAQ, while CBAY trades at $32.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRAY currently has a P/E ratio of -0.27, whereas CBAY's P/E ratio is -32.81. In terms of profitability, GRAY's ROE is +33.98%, compared to CBAY's ROE of -0.64%. Regarding short-term risk, GRAY is more volatile compared to CBAY. This indicates higher risk in terms of short-term price fluctuations for GRAY.Check CBAY's competition here
Tango Therapeutics, Inc. (NASDAQ: TNGX)
GRAY vs TNGX Comparison October 2026
Graybug Vision, Inc. (NASDAQ: GRAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRAY stands at 121M. In comparison, TNGX has a market cap of 3.7B. Regarding current trading prices, GRAY is priced at $5.50 on the NASDAQ, while TNGX trades at $23.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRAY currently has a P/E ratio of -0.27, whereas TNGX's P/E ratio is -27.19. In terms of profitability, GRAY's ROE is +33.98%, compared to TNGX's ROE of -0.26%. Regarding short-term risk, GRAY is more volatile compared to TNGX. This indicates higher risk in terms of short-term price fluctuations for GRAY.Check TNGX's competition here
AbCellera Biologics Inc. (NASDAQ: ABCL)
GRAY vs ABCL Comparison October 2026
Graybug Vision, Inc. (NASDAQ: GRAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRAY stands at 121M. In comparison, ABCL has a market cap of 3.7B. Regarding current trading prices, GRAY is priced at $5.50 on the NASDAQ, while ABCL trades at $12.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRAY currently has a P/E ratio of -0.27, whereas ABCL's P/E ratio is -22.26. In terms of profitability, GRAY's ROE is +33.98%, compared to ABCL's ROE of -0.17%. Regarding short-term risk, GRAY is more volatile compared to ABCL. This indicates higher risk in terms of short-term price fluctuations for GRAY.Check ABCL's competition here
SpringWorks Therapeutics, Inc. (NASDAQ: SWTX)
GRAY vs SWTX Comparison October 2026
Graybug Vision, Inc. (NASDAQ: GRAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRAY stands at 121M. In comparison, SWTX has a market cap of 3.5B. Regarding current trading prices, GRAY is priced at $5.50 on the NASDAQ, while SWTX trades at $46.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRAY currently has a P/E ratio of -0.27, whereas SWTX's P/E ratio is -13.78. In terms of profitability, GRAY's ROE is +33.98%, compared to SWTX's ROE of -0.47%. Regarding short-term risk, GRAY is more volatile compared to SWTX. This indicates higher risk in terms of short-term price fluctuations for GRAY.Check SWTX's competition here
Xenon Pharmaceuticals Inc. (NASDAQ: XENE)
GRAY vs XENE Comparison October 2026
Graybug Vision, Inc. (NASDAQ: GRAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRAY stands at 121M. In comparison, XENE has a market cap of 3.5B. Regarding current trading prices, GRAY is priced at $5.50 on the NASDAQ, while XENE trades at $36.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRAY currently has a P/E ratio of -0.27, whereas XENE's P/E ratio is -7.69. In terms of profitability, GRAY's ROE is +33.98%, compared to XENE's ROE of -0.44%. Regarding short-term risk, GRAY is more volatile compared to XENE. This indicates higher risk in terms of short-term price fluctuations for GRAY.Check XENE's competition here
Legend Biotech Corporation (NASDAQ: LEGN)
GRAY vs LEGN Comparison October 2026
Graybug Vision, Inc. (NASDAQ: GRAY) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, GRAY stands at 121M. In comparison, LEGN has a market cap of 3.5B. Regarding current trading prices, GRAY is priced at $5.50 on the NASDAQ, while LEGN trades at $18.62.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
GRAY currently has a P/E ratio of -0.27, whereas LEGN's P/E ratio is -27.51. In terms of profitability, GRAY's ROE is +33.98%, compared to LEGN's ROE of -0.09%. Regarding short-term risk, GRAY is more volatile compared to LEGN. This indicates higher risk in terms of short-term price fluctuations for GRAY.Check LEGN's competition here